These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 12375322

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients.
    Huong DL, Amoura Z, Duhaut P, Sbai A, Costedoat N, Wechsler B, Piette JC.
    J Rheumatol; 2002 Dec; 29(12):2571-6. PubMed ID: 12465154
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide.
    Katsifis GE, Tzioufas AG.
    Lupus; 2004 Dec; 13(9):673-8. PubMed ID: 15485101
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [The risk of sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy].
    Liu G, Chen Y, Wang L, Zuo C, Xie Q, Wang Z, Lin M.
    Hua Xi Yi Ke Da Xue Xue Bao; 2001 Jun; 32(2):294-5, 306. PubMed ID: 12600113
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The effect of menopause on disease activity in systemic lupus erythematosus.
    Urowitz MB, Ibañez D, Jerome D, Gladman DD.
    J Rheumatol; 2006 Nov; 33(11):2192-8. PubMed ID: 16981295
    [Abstract] [Full Text] [Related]

  • 14. [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].
    Petrović R, Stojanović R, Novicić-Sasić D, Dimitrijević J, Pavlović S, Stojković D, Palić-Obradović D, Stevanović G, Prodanović S.
    Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():19-25. PubMed ID: 12583309
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus.
    Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ.
    Arthritis Rheum; 2005 Sep; 52(9):2761-7. PubMed ID: 16142702
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXI. Disease activity, damage accrual, and vascular events in pre- and postmenopausal women.
    Fernández M, Calvo-Alén J, Alarcón GS, Roseman JM, Bastian HM, Fessler BJ, McGwin G, Vilá LM, Sanchez ML, Reveille JD.
    Arthritis Rheum; 2005 Jun; 52(6):1655-64. PubMed ID: 15934092
    [Abstract] [Full Text] [Related]

  • 20. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study.
    Manger K, Wildt L, Kalden JR, Manger B.
    Autoimmun Rev; 2006 Apr; 5(4):269-72. PubMed ID: 16697968
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.